F.D.A. Approves the Drug Daraxonrasib That’s Poised to Transform Pancreatic Cancer

In a key clinical trial, patients who got the pill, daraxonrasib, lived twice as long as those who got chemotherapy.

The top 3

Key Chemotherapy Regimens for Pancreatic Cancer: FOLFIRINOX, a multi-drug chemotherapy combination, significantly improves overall survival in metastatic pancreatic cancer compared to gemcitabine alone, with median overall survival of 11.1 months versus 6.8 months respectively. Another common regimen combines nab-paclitaxel with gemcitabine, which has also been shown to improve survival compared to gemcitabine monotherapy, with a median overall survival of 8.5 months versus 6.7 months.
Targeted Therapies and Immunotherapy Advancements: Daraxonrasib is a new oral targeted therapy that inhibits the active RAS protein, which is mutated in over 90% of pancreatic tumors, potentially doubling survival in previously treated metastatic pancreatic cancer patients. Immunotherapy, though generally having modest success rates below 5% in unselected pancreatic cancer patients, can be remarkably effective in the rare subgroup of tumors with microsatellite instability-high (MSI-H) or mismatch repair deficiency (dMMR), sometimes leading to long-term survival.
Surgical Options and Their Impact on Survival: Surgery remains the only curative treatment for pancreatic cancer, though only 10-20% of patients are candidates for resection. The Whipple procedure, a complex surgery, has a 5-year survival rate of approximately 20-25% when performed at high-volume centers, significantly improving from historical rates.